Inventor · disambiguated record
James R. Manning
Also filed as: MANNING JAMES · MANNING JAMES R
14 granted patents·9 pending applications·34 citations·filing 2014–2024
89Inventor score
Top patents by PatentIndex Score
23 records- 0192US11098051B2Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infectionsNOVARTIS AG·Filed 2017·Granted Aug 24, 2021·5 cites·19 claims
- 0292US10160764B2Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infectionsNOVARTIS AG·Filed 2017·Granted Dec 25, 2018·11 cites·29 claims
- 0391US11453677B2Tricyclic compounds useful to treat orthomyxovirus infectionsNOVARTIS AG·Filed 2020·Granted Sep 27, 2022·2 cites·14 claims
- 0484US9434719B23-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDHCAFERRO THOMAS RAYMOND·Filed 2014·Granted Sep 6, 2016·7 cites·16 claims
- 0584US2025011334A1Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infectionsNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0683US12252482B2Pyrazolopyridine derivatives and uses thereofNOVARTIS AG·Filed 2024·Granted Mar 18, 2025·0 cites·22 claims
- 0782US11629149B210-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenzaNOVARTIS AG·Filed 2019·Granted Apr 18, 2023·3 cites·4 claims
- 0882US2025282762A1Pyrazolopyridine derivatives and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 0981US10858366B2Tricyclic compounds useful to treat orthomyxovirus infectionsNOVARTIS AG·Filed 2017·Granted Dec 8, 2020·3 cites·20 claims
- 1080US9688672B23-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDHNOVARTIS AG·Filed 2016·Granted Jun 27, 2017·2 cites·14 claims
- 1179US12172984B2Pyrazolopyridine derivatives and uses thereofNOVARTIS AG·Filed 2023·Granted Dec 24, 2024·0 cites·30 claims
- 1277US2025034156A110-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating InfluenzaNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1374US12071441B210-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenzaNOVARTIS AG·Filed 2023·Granted Aug 27, 2024·0 cites·4 claims
- 1473US11912715B2Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infectionsNOVARTIS AG·Filed 2021·Granted Feb 27, 2024·0 cites·22 claims
- 1573US11787785B2Pyrazolopyridine derivatives and uses thereofNOVARTIS AG·Filed 2022·Granted Oct 17, 2023·0 cites·15 claims
- 1669US9550762B2Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2015·Granted Jan 24, 2017·1 cites·95 claims
- 1759US2014275083A13-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idhCAFERRO THOMAS RAYMOND·Filed 2014·Application pending·0 cites
- 1857US10112931B23-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDHNOVARTIS AG·Filed 2017·Granted Oct 30, 2018·0 cites·11 claims
- 1956US2025276964A1Benzisoxazole Derivatives and Uses thereofNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2049US2022363671A1Glue degraders and methods of use thereofNOVARTIS AG·Filed 2020·Application pending·0 cites
- 2146US2017267673A1Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of useAMGEN INC·Filed 2016·Application pending·0 cites
- 2245US2020407365A1Indole-2-carbonyl compounds and their use for the treatment of hepatitis bNOVARTIS AG·Filed 2019·Application pending·0 cites
- 2343US2021079015A1Novel dihydroisoxazole compounds and their use for the treatment of hepatitis bNOVARTIS AG·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when James R. Manning files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →